Titre
Sustained improvement in left ventricular function after bone marrow derived cell therapy in patients with acute ST elevation myocardial infarction. A 5-year follow-up from the Stem Cell Transplantation in Ischaemic Myocardium Study.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Moccetti, T.
Auteure/Auteur
Sürder, D.
Auteure/Auteur
Klersy, C.
Auteure/Auteur
Vassalli, G.
Auteure/Auteur
Crljenica, C.
Auteure/Auteur
Rossi, M.G.
Auteure/Auteur
Pasotti, E.
Auteure/Auteur
Soldati, G.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
1424-3997
Statut éditorial
Publié
Date de publication
2012
Volume
142
Numéro
w13632
Première page
1
Dernière page/numéro d’article
11
Langue
anglais
Notes
Publication types: Controlled Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov't Publication Status: epublish
Résumé
BACKGROUND: Intracoronary injection of autologous bone marrow-derived mononucleated cells (BM-MNC) may improve LV function shortly after acute ST elevation myocardial infarction (STEMI), but little is known about the long-term durability of the treatment effect.
METHODS: In a single-centre trial a total of 60 patients with acute anterior STEMI, successful reperfusion therapy and a left ventricular ejection fraction (LVEF) of <50% were screened for the study. 23 patients were actively treated with intracoronary infusion of BM-MNC within a median of 3 days. The open-label control group consisted of 19 patients who did not consent to undergo BM-MNC treatment but agreed to undergo regular clinical and echocardiographic follow-up for up to 5 years after AMI.
RESULTS: Whereas at 4 months there was no significant difference between the increase in LVEF in the BM-MNC group and the control group (+7.0%, 95%CI 3.6; 10.4) vs. +3.9%, 95%CI -2.1; 10), the absolute increase at 5 years remained stable in the BM-MNC but not in the control group (+7.95%, 95%CI 3.5; 12.4 vs. -0.5%, 95%CI -5.4; 4.4; p for interaction between groups = 0.035).
DISCUSSION: In this single-centre, open-labelled study, intracoronary administration of BM-MNC is feasible and safe in the short term. It is also associated with sustained improvement of left ventricular function in patients with acute myocardial infarction, encouraging phase III studies to examine the potential BM-MNC effect on clinical outcome.
METHODS: In a single-centre trial a total of 60 patients with acute anterior STEMI, successful reperfusion therapy and a left ventricular ejection fraction (LVEF) of <50% were screened for the study. 23 patients were actively treated with intracoronary infusion of BM-MNC within a median of 3 days. The open-label control group consisted of 19 patients who did not consent to undergo BM-MNC treatment but agreed to undergo regular clinical and echocardiographic follow-up for up to 5 years after AMI.
RESULTS: Whereas at 4 months there was no significant difference between the increase in LVEF in the BM-MNC group and the control group (+7.0%, 95%CI 3.6; 10.4) vs. +3.9%, 95%CI -2.1; 10), the absolute increase at 5 years remained stable in the BM-MNC but not in the control group (+7.95%, 95%CI 3.5; 12.4 vs. -0.5%, 95%CI -5.4; 4.4; p for interaction between groups = 0.035).
DISCUSSION: In this single-centre, open-labelled study, intracoronary administration of BM-MNC is feasible and safe in the short term. It is also associated with sustained improvement of left ventricular function in patients with acute myocardial infarction, encouraging phase III studies to examine the potential BM-MNC effect on clinical outcome.
PID Serval
serval:BIB_16FA37BE7D5A
PMID
Open Access
Oui
Date de création
2013-02-06T08:38:58.314Z
Date de création dans IRIS
2025-05-20T20:30:44Z
Fichier(s)![Vignette d'image]()
En cours de chargement...
Nom
BIB_16FA37BE7D5A.P001.pdf
Version du manuscrit
preprint
Taille
731.11 KB
Format
Adobe PDF
PID Serval
serval:BIB_16FA37BE7D5A.P001
URN
urn:nbn:ch:serval-BIB_16FA37BE7D5A9
Somme de contrôle
(MD5):c0d3d313c788cca2a0d17b18bd772c7c